Sinemet CR (Carbidopa / Levodopa) - Summary

SINEMET CR SUMMARY

SINEMET^® CR
(CARBIDOPA-LEVODOPA)
SUSTAINED-RELEASE TABLETS

SINEMET* CR (Carbidopa-Levodopa) is a sustained-release combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome.

SINEMET CR is indicated in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.

SINEMET CR NEWS HIGHLIGHTS

Published Studies Related to Sinemet CR (Carbidopa / Levodopa)

Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. [2007.05.11]

Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. [2005.05]

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. [2004.01]

[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study] [2003.06]

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. [2000.05]

more>>

Clinical Trials Related to Sinemet CR (Carbidopa / Levodopa)

Comparison of IPX054, Immediate-Release Carbidopa-Levodopa, and Controlled-Release Carbidopa-Levodopa in Subjects With Parkinson's Disease [Recruiting]

A Single Center, Randomized, Double-Blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopaâ„¢ With Sinemet® in Subjects With Stable Parkinson's Disease [Completed]

A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects [Completed]

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease [Recruiting]

A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease [Completed]

more>>